Skip to main content
Top

17-06-2024 | Thyroid Cancer | Original Article

A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma

Authors: Tahereh Haghzad, Babak Khorsand, S. Adeleh Razavi, Mehdi Hedayati

Published in: Endocrine

Login to get access

Abstract

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, posing a growing clinical challenge. PTC exhibits two age-related peaks, with established risk factors including family history and radiation exposure. Managing even low-risk, localized PTC cases remain complex, with growing interest in active surveillance as an alternative to immediate surgery. This study employed single-cell RNA sequencing (scRNA-Seq) to explore the predictive value of BRAF and RAS mutations in PTC, shedding light on their impact on disease progression and outcomes. The analyses emphasized the significance of BRAF and RAS mutations in tumor advancement, particularly the unique BRAF V600E mutation associated with aggressive features. The methodology involved scRNA-Seq analysis of PTC and normal samples, unveiling distinct cell clusters and indicating upregulated BRAF and RAS genes. Pathway enrichment analysis highlighted altered biological processes and immune-related pathways in PTC. The study consolidated previous research showing the prevalence of BRAF and RAS mutations in PTC, subtypes with distinct molecular profiles, and the impact of TERT promoter mutations on disease severity. In summary, this study unveils the complex interplay of genetic mutations and the cellular microenvironment in PTC through scRNA-Seq. The upregulated BRAF and RAS genes suggest their roles as PTC drivers, and pathway enrichment reveals alterations in immune-related processes. This synthesis of prior research enhances our understanding of PTC’s molecular foundations, informing better prognosis and personalized treatment approaches. These insights advance the landscape of PTC management and provide directions for further research.
Appendix
Available only for authorised users
Literature
1.
go back to reference S. Al-Salam, C. Sharma, B. Afandi, BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. PLoS One 15(4), e0231341 (2020)PubMedPubMedCentral S. Al-Salam, C. Sharma, B. Afandi, BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. PLoS One 15(4), e0231341 (2020)PubMedPubMedCentral
2.
go back to reference J.A. Sosa, R. Udelsman, Papillary thyroid cancer. Surg. Oncol. Clin. North Am. 15(3), 585–601 (2006) J.A. Sosa, R. Udelsman, Papillary thyroid cancer. Surg. Oncol. Clin. North Am. 15(3), 585–601 (2006)
3.
go back to reference C.C. Juhlin, O. Mete, Z.W. Baloch, The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr. Related Cancer. ERC-22 (2022) C.C. Juhlin, O. Mete, Z.W. Baloch, The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr. Related Cancer. ERC-22 (2022)
4.
go back to reference R.W. Randle, N.M. Bushman, J. Orne, C.J. Balentine, E. Wendt, M. Saucke et al. Papillary thyroid cancer: the good and bad of the “good cancer”. Thyroid. Off. J. Am. Thyroid. Assoc. 27(7), 902–907 (2017) R.W. Randle, N.M. Bushman, J. Orne, C.J. Balentine, E. Wendt, M. Saucke et al. Papillary thyroid cancer: the good and bad of the “good cancer”. Thyroid. Off. J. Am. Thyroid. Assoc. 27(7), 902–907 (2017)
5.
go back to reference J.P. Brito, I.D. Hay, J.C. Morris, Low risk papillary thyroid cancer. BMJ (Clin. Res. ed.) 348, g3045 (2014) J.P. Brito, I.D. Hay, J.C. Morris, Low risk papillary thyroid cancer. BMJ (Clin. Res. ed.) 348, g3045 (2014)
6.
go back to reference I. Petrini, R.L. Cecchini, M. Mascaró, I. Ponzoni, J.A. Carballido, Papillary thyroid carcinoma: a thorough bioinformatic analysis of gene expression and clinical data. Genes 14(6), 1250 (2023)PubMedPubMedCentral I. Petrini, R.L. Cecchini, M. Mascaró, I. Ponzoni, J.A. Carballido, Papillary thyroid carcinoma: a thorough bioinformatic analysis of gene expression and clinical data. Genes 14(6), 1250 (2023)PubMedPubMedCentral
7.
go back to reference M. Hedayati, S. Rajabi, A. Nikzamir, Papillary thyroid cancer-promoting activities of combined oral contraceptive components. Galen. Med. J. 9, e1648 (2020)PubMedPubMedCentral M. Hedayati, S. Rajabi, A. Nikzamir, Papillary thyroid cancer-promoting activities of combined oral contraceptive components. Galen. Med. J. 9, e1648 (2020)PubMedPubMedCentral
8.
go back to reference E. Kyrodimos, A. Chrysovergis, N. Mastronikolis, G. Papanastasiou, E. Tsiambas, D. Spyropoulou, et al. The landscape of single nucleotide polymorphisms in papillary thyroid carcinoma. Cancer Diagn Progn. 3(1), 26 (2023). E. Kyrodimos, A. Chrysovergis, N. Mastronikolis, G. Papanastasiou, E. Tsiambas, D. Spyropoulou, et al. The landscape of single nucleotide polymorphisms in papillary thyroid carcinoma. Cancer Diagn Progn. 3(1), 26 (2023).
9.
go back to reference X. Nie, J. Shang, W. Wang, TERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma. Front. Surg. 9, 1019180 (2023)PubMedPubMedCentral X. Nie, J. Shang, W. Wang, TERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma. Front. Surg. 9, 1019180 (2023)PubMedPubMedCentral
10.
go back to reference J.I. Staubitz, C. Müller, A. Heymans, C. Merten, B. Roos, A. Poplawski et al. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis. BJS Open 7(3), zrad029 (2023)PubMedPubMedCentral J.I. Staubitz, C. Müller, A. Heymans, C. Merten, B. Roos, A. Poplawski et al. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis. BJS Open 7(3), zrad029 (2023)PubMedPubMedCentral
11.
go back to reference M. Xing, BRAF mutation in thyroid cancer. Endocr.-Relat. Cancer Endocr. Relat. Cancer 12(2), 245–262 (2005)PubMed M. Xing, BRAF mutation in thyroid cancer. Endocr.-Relat. Cancer Endocr. Relat. Cancer 12(2), 245–262 (2005)PubMed
12.
go back to reference S. Li, A. Balmain, C.M. Counter, A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18(12), 767–777 (2018)PubMed S. Li, A. Balmain, C.M. Counter, A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18(12), 767–777 (2018)PubMed
13.
go back to reference S.A. Razavi, P. Salehipour, H. Gholami, S. Sheikholeslami, M. Zarif-Yeganeh, P. Yaghmaei et al. New evidence on tumor suppressor activity of PTEN and KLLN in papillary thyroid carcinoma. Pathol. Res. Pract. 225, 153586 (2021)PubMed S.A. Razavi, P. Salehipour, H. Gholami, S. Sheikholeslami, M. Zarif-Yeganeh, P. Yaghmaei et al. New evidence on tumor suppressor activity of PTEN and KLLN in papillary thyroid carcinoma. Pathol. Res. Pract. 225, 153586 (2021)PubMed
14.
go back to reference J. Lim, H.S. Lee, J. Park, K.-S. Kim, S.-K. Kim, Y.-W. Cho, Y.S. Song, Different molecular phenotypes of progression in BRAF-and RAS-like papillary thyroid carcinoma. Endocrinol. Metab. 38(4), 445–454 (2023) J. Lim, H.S. Lee, J. Park, K.-S. Kim, S.-K. Kim, Y.-W. Cho, Y.S. Song, Different molecular phenotypes of progression in BRAF-and RAS-like papillary thyroid carcinoma. Endocrinol. Metab. 38(4), 445–454 (2023)
15.
go back to reference T. Wang, J. Shi, L. Li, X. Zhou, H. Zhang, X. Zhang et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma. Front. Immunol. 13, 840811 (2022)PubMedPubMedCentral T. Wang, J. Shi, L. Li, X. Zhou, H. Zhang, X. Zhang et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma. Front. Immunol. 13, 840811 (2022)PubMedPubMedCentral
16.
go back to reference L. Lu, J.R. Wang, Y.C. Henderson, S. Bai, J. Yang, M. Hu et al. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J. Clin. Investig. 133(11), e169653 (2023)PubMedPubMedCentral L. Lu, J.R. Wang, Y.C. Henderson, S. Bai, J. Yang, M. Hu et al. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J. Clin. Investig. 133(11), e169653 (2023)PubMedPubMedCentral
17.
go back to reference W.J. Pereira, F.M. Almeida, D. Conde, K. Balmant, P. Triozzi, H. Schmidt et al. Asc-Seurat: analytical single-cell Seurat-based web application. BMC Bioinforma. 22, 1–14 (2021) W.J. Pereira, F.M. Almeida, D. Conde, K. Balmant, P. Triozzi, H. Schmidt et al. Asc-Seurat: analytical single-cell Seurat-based web application. BMC Bioinforma. 22, 1–14 (2021)
18.
go back to reference T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W.M. Mauck et al. Comprehensive integration of single-cell data. Cell 177(7), 1888–902. e21 (2019)PubMedPubMedCentral T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W.M. Mauck et al. Comprehensive integration of single-cell data. Cell 177(7), 1888–902. e21 (2019)PubMedPubMedCentral
19.
go back to reference A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36(5), 411–420 (2018)PubMedPubMedCentral A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36(5), 411–420 (2018)PubMedPubMedCentral
20.
go back to reference Y. Hao, T. Stuart, M.H. Kowalski, S. Choudhary, P. Hoffman, A. Hartman et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42(2), 293–304 (2024)PubMed Y. Hao, T. Stuart, M.H. Kowalski, S. Choudhary, P. Hoffman, A. Hartman et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42(2), 293–304 (2024)PubMed
21.
go back to reference M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu et al. Tissue-based map of the human proteome. Science 347(6220), 1260419 (2015)PubMed M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu et al. Tissue-based map of the human proteome. Science 347(6220), 1260419 (2015)PubMed
22.
go back to reference C. Hu, T. Li, Y. Xu, X. Zhang, F. Li, J. Bai et al. CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 51(D1), D870–D876 (2023)PubMed C. Hu, T. Li, Y. Xu, X. Zhang, F. Li, J. Bai et al. CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 51(D1), D870–D876 (2023)PubMed
23.
go back to reference M. Zarkesh, A. Zadeh-Vakili, F. Azizi, S.A. Fanaei, F. Foroughi, M. Hedayati, The association of BRAF V600E mutation with tissue inhibitor of metalloproteinase-3 expression and clinicopathological features in papillary thyroid cancer. Int. J. Endocrinol. Metab. 16(2), e56120 (2018)PubMedPubMedCentral M. Zarkesh, A. Zadeh-Vakili, F. Azizi, S.A. Fanaei, F. Foroughi, M. Hedayati, The association of BRAF V600E mutation with tissue inhibitor of metalloproteinase-3 expression and clinicopathological features in papillary thyroid cancer. Int. J. Endocrinol. Metab. 16(2), e56120 (2018)PubMedPubMedCentral
24.
go back to reference S.A. Razavi, M.H. Modarressi, P. Yaghmaei, S.M. Tavangar, M. Hedayati, Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers? Endocrine 57, 428–435 (2017)PubMed S.A. Razavi, M.H. Modarressi, P. Yaghmaei, S.M. Tavangar, M. Hedayati, Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers? Endocrine 57, 428–435 (2017)PubMed
25.
go back to reference J.-F. Hang, J.-Y. Chen, P.-C. Kuo, H.-F. Lai, T.-L. Lee, S.-K. Tai et al. A shift in molecular drivers of papillary thyroid carcinoma following the 2017 World Health Organization Classification: characterization of 554 consecutive tumors with emphasis on BRAF-negative cases. Mod. Pathol. 36(9), 100242 (2023)PubMed J.-F. Hang, J.-Y. Chen, P.-C. Kuo, H.-F. Lai, T.-L. Lee, S.-K. Tai et al. A shift in molecular drivers of papillary thyroid carcinoma following the 2017 World Health Organization Classification: characterization of 554 consecutive tumors with emphasis on BRAF-negative cases. Mod. Pathol. 36(9), 100242 (2023)PubMed
26.
go back to reference S.-Y. Kim, S.-J. Shin, D.-G. Lee, H.-J. Yun, S.-M. Kim, H. Chang et al. Clinicopathological and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma. Cancers 15(12), 3101 (2023)PubMedPubMedCentral S.-Y. Kim, S.-J. Shin, D.-G. Lee, H.-J. Yun, S.-M. Kim, H. Chang et al. Clinicopathological and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma. Cancers 15(12), 3101 (2023)PubMedPubMedCentral
27.
go back to reference C. Eloy, J. Santos, P. Soares, M. Sobrinho-Simões, The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 459(3), 265–276 (2011)PubMed C. Eloy, J. Santos, P. Soares, M. Sobrinho-Simões, The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 459(3), 265–276 (2011)PubMed
28.
go back to reference Y.C. Henderson, T.D. Shellenberger, M.D. Williams, A.K. El-Naggar, M.J. Fredrick, K.M. Cieply, G.L. Clayman, High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 15(2), 485–491 (2009) Y.C. Henderson, T.D. Shellenberger, M.D. Williams, A.K. El-Naggar, M.J. Fredrick, K.M. Cieply, G.L. Clayman, High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 15(2), 485–491 (2009)
29.
go back to reference M. Rivera, J. Ricarte-Filho, J. Knauf, A. Shaha, M. Tuttle, J.A. Fagin, R.A. Ghossein, Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod. Pathol. 23(9), 1191–1200 (2010)PubMedPubMedCentral M. Rivera, J. Ricarte-Filho, J. Knauf, A. Shaha, M. Tuttle, J.A. Fagin, R.A. Ghossein, Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod. Pathol. 23(9), 1191–1200 (2010)PubMedPubMedCentral
30.
go back to reference S. Hong, Y. Xie, Z. Cheng, J. Li, Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability. Oncogene 41(47), 5121–5132 (2022)PubMedPubMedCentral S. Hong, Y. Xie, Z. Cheng, J. Li, Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability. Oncogene 41(47), 5121–5132 (2022)PubMedPubMedCentral
31.
go back to reference V. Veschi, A. Turdo, Recapitulating thyroid cancer histotypes through engineering embryonic stem cells. Nat. Commun. 14(1), 1351 (2023)PubMedPubMedCentral V. Veschi, A. Turdo, Recapitulating thyroid cancer histotypes through engineering embryonic stem cells. Nat. Commun. 14(1), 1351 (2023)PubMedPubMedCentral
32.
go back to reference M. Matsuse, T. Yabuta, V. Saenko, M. Hirokawa, E. Nishihara, K. Suzuki et al. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci. Rep. 7, 41752 (2017)PubMedPubMedCentral M. Matsuse, T. Yabuta, V. Saenko, M. Hirokawa, E. Nishihara, K. Suzuki et al. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci. Rep. 7, 41752 (2017)PubMedPubMedCentral
33.
go back to reference Y.E. Nikiforov, Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 21(Suppl 2), S37–S43 (2008)PubMedPubMedCentral Y.E. Nikiforov, Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 21(Suppl 2), S37–S43 (2008)PubMedPubMedCentral
34.
go back to reference J. Vinagre, A. Almeida, H. Pópulo, R. Batista, J. Lyra, V. Pinto et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013)PubMed J. Vinagre, A. Almeida, H. Pópulo, R. Batista, J. Lyra, V. Pinto et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013)PubMed
35.
go back to reference L. Goedert, J.R. Plaça, C.S. Fuziwara, Identification of long noncoding RNAs deregulated in papillary thyroid cancer and correlated with BRAF(V600E) mutation by bioinformatics integrative analysis. Sci. Rep. 7(1), 1662 (2017)PubMedPubMedCentral L. Goedert, J.R. Plaça, C.S. Fuziwara, Identification of long noncoding RNAs deregulated in papillary thyroid cancer and correlated with BRAF(V600E) mutation by bioinformatics integrative analysis. Sci. Rep. 7(1), 1662 (2017)PubMedPubMedCentral
36.
go back to reference B. Khorsand, A. Savadi, M. Naghibzadeh, Parallelizing assignment problem with DNA strands. Iran. J. Biotechnol. 18(1), e2547 (2020)PubMedPubMedCentral B. Khorsand, A. Savadi, M. Naghibzadeh, Parallelizing assignment problem with DNA strands. Iran. J. Biotechnol. 18(1), e2547 (2020)PubMedPubMedCentral
37.
go back to reference B. Khorsand, A. Khammari, N. Shirvanizadeh, J. Zahiri, S.S. Arab, OligoCOOL: a mobile application for nucleotide sequence analysis. Biochem. Mol. Biol. Educ. 47(2), 201–206 (2019)PubMed B. Khorsand, A. Khammari, N. Shirvanizadeh, J. Zahiri, S.S. Arab, OligoCOOL: a mobile application for nucleotide sequence analysis. Biochem. Mol. Biol. Educ. 47(2), 201–206 (2019)PubMed
38.
go back to reference M. Zou, E.Y. Baitei, A.S. Alzahrani, F.S. BinHumaid, D. Alkhafaji, R.A. Al-Rijjal et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. Off. J. Am. Thyroid. Assoc. 24(8), 1256–1266 (2014) M. Zou, E.Y. Baitei, A.S. Alzahrani, F.S. BinHumaid, D. Alkhafaji, R.A. Al-Rijjal et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. Off. J. Am. Thyroid. Assoc. 24(8), 1256–1266 (2014)
39.
go back to reference S. Beg, A. Siraj, Z. Jehan, S. Prabakaran, S. Al-Sobhi, M. Al-Dawish et al. PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. Br. J. Cancer 112(12), 1938–1943 (2015)PubMedPubMedCentral S. Beg, A. Siraj, Z. Jehan, S. Prabakaran, S. Al-Sobhi, M. Al-Dawish et al. PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. Br. J. Cancer 112(12), 1938–1943 (2015)PubMedPubMedCentral
40.
go back to reference M. Shimamura, N. Shibusawa, T. Kurashige, Z. Mussazhanova, H. Matsuzaki, M. Nakashima et al. Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels. PloS One 13(8), e0201365 (2018)PubMedPubMedCentral M. Shimamura, N. Shibusawa, T. Kurashige, Z. Mussazhanova, H. Matsuzaki, M. Nakashima et al. Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels. PloS One 13(8), e0201365 (2018)PubMedPubMedCentral
41.
go back to reference H.S. Min, C. Lee, K.C. Jung, Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J. Korean Med. Sci. 28(4), 534–541 (2013)PubMedPubMedCentral H.S. Min, C. Lee, K.C. Jung, Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J. Korean Med. Sci. 28(4), 534–541 (2013)PubMedPubMedCentral
42.
43.
go back to reference G. Gandolfi, M. Ragazzi, A. Frasoldati, S. Piana, A. Ciarrocchi, V. Sancisi, TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur. J. Endocrinol. 172(4), 403–413 (2015)PubMed G. Gandolfi, M. Ragazzi, A. Frasoldati, S. Piana, A. Ciarrocchi, V. Sancisi, TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur. J. Endocrinol. 172(4), 403–413 (2015)PubMed
44.
go back to reference C. Liu, Z. Liu, T. Chen, W. Zeng, Y. Guo, T. Huang, TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Sci. Rep. 6(1), 36990 (2016)PubMedPubMedCentral C. Liu, Z. Liu, T. Chen, W. Zeng, Y. Guo, T. Huang, TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Sci. Rep. 6(1), 36990 (2016)PubMedPubMedCentral
45.
go back to reference R. Liu, J. Bishop, G. Zhu, T. Zhang, P.W. Ladenson, M. Xing, Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 3(2), 202–208 (2017)PubMed R. Liu, J. Bishop, G. Zhu, T. Zhang, P.W. Ladenson, M. Xing, Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 3(2), 202–208 (2017)PubMed
46.
go back to reference G. Landskron, M. De la Fuente, P. Thuwajit, C. Thuwajit, M.A. Hermoso, Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 149185 (2014)PubMedPubMedCentral G. Landskron, M. De la Fuente, P. Thuwajit, C. Thuwajit, M.A. Hermoso, Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 149185 (2014)PubMedPubMedCentral
47.
go back to reference T.E. Angell, M.G. Lechner, J.K. Jang, A.J. Correa, J.S. LoPresti, A.L. Epstein, BRAFV600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24(9), 1385–1393 (2014)PubMedPubMedCentral T.E. Angell, M.G. Lechner, J.K. Jang, A.J. Correa, J.S. LoPresti, A.L. Epstein, BRAFV600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24(9), 1385–1393 (2014)PubMedPubMedCentral
48.
go back to reference M.A. Nengroo, S. Maheshwari, A. Singh, A. Verma, R.K. Arya, P. Chaturvedi et al. CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5. Cell Death Dis. 12(5), 464 (2021)PubMedPubMedCentral M.A. Nengroo, S. Maheshwari, A. Singh, A. Verma, R.K. Arya, P. Chaturvedi et al. CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5. Cell Death Dis. 12(5), 464 (2021)PubMedPubMedCentral
49.
go back to reference C. Caperton, The Dichotomous Role of Immune Cells in Thyroid Cancer Pathogenesis (University of Arkansas for Medical Sciences, 2021). C. Caperton, The Dichotomous Role of Immune Cells in Thyroid Cancer Pathogenesis (University of Arkansas for Medical Sciences, 2021).
50.
go back to reference D. Serban, J. Leng, D. Cheresh, H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 102(11), 1350–1358 (2008)PubMedPubMedCentral D. Serban, J. Leng, D. Cheresh, H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 102(11), 1350–1358 (2008)PubMedPubMedCentral
51.
go back to reference M. Aprile, S. Cataldi, C. Perfetto, A. Federico, Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype. Br. J. Cancer 129(2), 249–265 (2023)PubMedPubMedCentral M. Aprile, S. Cataldi, C. Perfetto, A. Federico, Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype. Br. J. Cancer 129(2), 249–265 (2023)PubMedPubMedCentral
52.
go back to reference M.S. Brose, M.E. Cabanillas, E.E. Cohen, L.J. Wirth, T. Riehl, H. Yue et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17(9), 1272–1282 (2016)PubMedPubMedCentral M.S. Brose, M.E. Cabanillas, E.E. Cohen, L.J. Wirth, T. Riehl, H. Yue et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17(9), 1272–1282 (2016)PubMedPubMedCentral
53.
go back to reference E.A. Agyekum, Y.-g Wang, F.-J. Xu, D. Akortia, Y.-z Ren, K.H. Chambers et al. Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography. Sci. Rep. 13(1), 12604 (2023)PubMedPubMedCentral E.A. Agyekum, Y.-g Wang, F.-J. Xu, D. Akortia, Y.-z Ren, K.H. Chambers et al. Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography. Sci. Rep. 13(1), 12604 (2023)PubMedPubMedCentral
54.
go back to reference L.X. Ma, O. Espin-Garcia, P.L. Bedard, T. Stockley, R. Prince, O. Mete, M.K. Krzyzanowska, Clinical application of next-generation sequencing in advanced thyroid cancers. Thyroid. Off. J. Am. Thyroid. Assoc. 32(6), 657–666 (2022) L.X. Ma, O. Espin-Garcia, P.L. Bedard, T. Stockley, R. Prince, O. Mete, M.K. Krzyzanowska, Clinical application of next-generation sequencing in advanced thyroid cancers. Thyroid. Off. J. Am. Thyroid. Assoc. 32(6), 657–666 (2022)
55.
go back to reference J. Desai, H. Gan, C. Barrow, M. Jameson, V. Atkinson, A. Haydon et al. Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors. J. Clin. Oncol. 38(19), 2140 (2020)PubMedPubMedCentral J. Desai, H. Gan, C. Barrow, M. Jameson, V. Atkinson, A. Haydon et al. Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors. J. Clin. Oncol. 38(19), 2140 (2020)PubMedPubMedCentral
56.
go back to reference J.B. Groener, D. Gelen, C. Mogler, E. Herpel, C. Toth, Z. Kender et al. BRAF V600E and retinoic acid in radioiodine-refractory papillary thyroid cancer. Horm. Metab. Res. 51(01), 69–75 (2019)PubMed J.B. Groener, D. Gelen, C. Mogler, E. Herpel, C. Toth, Z. Kender et al. BRAF V600E and retinoic acid in radioiodine-refractory papillary thyroid cancer. Horm. Metab. Res. 51(01), 69–75 (2019)PubMed
57.
go back to reference L. Sisdelli, M.I.C.V. Cordioli, F. Vaisman, L. Moraes, G.A. Colozza‐Gama, P.A.G. Alves Jr et al. AGK‐BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma. Pediatr. Blood Cancer 66(7), e27707 (2019)PubMed L. Sisdelli, M.I.C.V. Cordioli, F. Vaisman, L. Moraes, G.A. Colozza‐Gama, P.A.G. Alves Jr et al. AGK‐BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma. Pediatr. Blood Cancer 66(7), e27707 (2019)PubMed
58.
go back to reference S. Kure, K. Ishino, M. Kudo, R. Wada, M. Saito, R. Nagaoka et al. Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience. J. Int. Med. Res. 47(11), 5560–5572 (2019)PubMedPubMedCentral S. Kure, K. Ishino, M. Kudo, R. Wada, M. Saito, R. Nagaoka et al. Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience. J. Int. Med. Res. 47(11), 5560–5572 (2019)PubMedPubMedCentral
59.
go back to reference Z. Liu, T. Lv, C. Xie, Z. Di, BRAF V600E gene mutation is associated with bilateral malignancy of papillary thyroid cancer. Am. J. Med. Sci. 356(2), 130–134 (2018)PubMed Z. Liu, T. Lv, C. Xie, Z. Di, BRAF V600E gene mutation is associated with bilateral malignancy of papillary thyroid cancer. Am. J. Med. Sci. 356(2), 130–134 (2018)PubMed
60.
go back to reference J. Li, J. Liu, X. Yu, X. Bao, L. Qian, BRAFv600e mutation combined with thyroglobulin and fine-needle aspiration in diagnosis of lymph node metastasis of papillary thyroid carcinoma. Pathol. Res. Pract. 214(11), 1892–1897 (2018)PubMed J. Li, J. Liu, X. Yu, X. Bao, L. Qian, BRAFv600e mutation combined with thyroglobulin and fine-needle aspiration in diagnosis of lymph node metastasis of papillary thyroid carcinoma. Pathol. Res. Pract. 214(11), 1892–1897 (2018)PubMed
61.
go back to reference M.P. Fano, A.U. Olano, E.F. Thomas, A.O. Alday, Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Endocrinol. Diabetes Nutr 64(2), 75–81 (2017) M.P. Fano, A.U. Olano, E.F. Thomas, A.O. Alday, Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Endocrinol. Diabetes Nutr 64(2), 75–81 (2017)
62.
go back to reference H. Jin, Y. Liang, X. Wang, J. Zhu, R. Sun, P. Chen et al. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med. Oncol. 31, 1–5 (2014) H. Jin, Y. Liang, X. Wang, J. Zhu, R. Sun, P. Chen et al. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med. Oncol. 31, 1–5 (2014)
63.
go back to reference L.E. Henke, S.M. Perkins, J.D. Pfeifer, C. Ma, Y. Chen, T. DeWees, P.W. Grigsby, BRAF V600E mutational status in pediatric thyroid cancer. Pediatr. Blood Cancer 61(7), 1168–1172 (2014)PubMed L.E. Henke, S.M. Perkins, J.D. Pfeifer, C. Ma, Y. Chen, T. DeWees, P.W. Grigsby, BRAF V600E mutational status in pediatric thyroid cancer. Pediatr. Blood Cancer 61(7), 1168–1172 (2014)PubMed
64.
go back to reference K.B. Kim, M.E. Cabanillas, A.J. Lazar, M.D. Williams, D.L. Sanders, J.L. Ilagan et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation. Thyroid. Off. J. Am. Thyroid. Assoc. 23(10), 1277–1283 (2013) K.B. Kim, M.E. Cabanillas, A.J. Lazar, M.D. Williams, D.L. Sanders, J.L. Ilagan et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation. Thyroid. Off. J. Am. Thyroid. Assoc. 23(10), 1277–1283 (2013)
65.
go back to reference B. Brahma, E.D. Yulian, M. Ramli, I. Setianingsih, W. Gautama, P. Brahma et al. Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma. Asian Pac. J. Cancer Prev. 14(1), 31–37 (2013)PubMed B. Brahma, E.D. Yulian, M. Ramli, I. Setianingsih, W. Gautama, P. Brahma et al. Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma. Asian Pac. J. Cancer Prev. 14(1), 31–37 (2013)PubMed
66.
go back to reference C. Leux, T. Truong, C. Petit, D. Baron-Dubourdieu, P. Guénel, Family history of malignant and benign thyroid diseases and risk of thyroid cancer: a population-based case–control study in New Caledonia. Cancer Causes Control 23, 745–755 (2012)PubMed C. Leux, T. Truong, C. Petit, D. Baron-Dubourdieu, P. Guénel, Family history of malignant and benign thyroid diseases and risk of thyroid cancer: a population-based case–control study in New Caledonia. Cancer Causes Control 23, 745–755 (2012)PubMed
67.
go back to reference D.S. Hong, M.E. Cabanillas, J. Wheler, A. Naing, A.M. Tsimberidou, L. Ye et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 96(4), 997–1005 (2011)PubMedPubMedCentral D.S. Hong, M.E. Cabanillas, J. Wheler, A. Naing, A.M. Tsimberidou, L. Ye et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 96(4), 997–1005 (2011)PubMedPubMedCentral
68.
go back to reference A. Mathur, W. Moses, R. Rahbari, E. Khanafshar, Q.Y. Duh, O. Clark, E. Kebebew, Higher rate of BRAF mutation in papillary thyroid cancer over time: a single‐institution study. Cancer 117(19), 4390–4395 (2011)PubMed A. Mathur, W. Moses, R. Rahbari, E. Khanafshar, Q.Y. Duh, O. Clark, E. Kebebew, Higher rate of BRAF mutation in papillary thyroid cancer over time: a single‐institution study. Cancer 117(19), 4390–4395 (2011)PubMed
69.
go back to reference G.M. Howell, S.E. Carty, M.J. Armstrong, S.O. LeBeau, S.P. Hodak, C. Coyne et al. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann. Surg. Oncol. 18, 3566–3571 (2011)PubMed G.M. Howell, S.E. Carty, M.J. Armstrong, S.O. LeBeau, S.P. Hodak, C. Coyne et al. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann. Surg. Oncol. 18, 3566–3571 (2011)PubMed
70.
go back to reference E.J. Lee, K.H. Song, D.L. Kim, Y.M. Jang, T.S. Hwang, S.K. Kim, The BRAFV600E mutation is associated with malignant ultrasonographic features in thyroid nodules. Clin. Endocrinol. 75(6), 844–850 (2011) E.J. Lee, K.H. Song, D.L. Kim, Y.M. Jang, T.S. Hwang, S.K. Kim, The BRAFV600E mutation is associated with malignant ultrasonographic features in thyroid nodules. Clin. Endocrinol. 75(6), 844–850 (2011)
71.
go back to reference M. Xing, R.P. Tufano, A.P. Tufaro, S. Basaria, M. Ewertz, E. Rosenbaum et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 89(6), 2867–2872 (2004)PubMed M. Xing, R.P. Tufano, A.P. Tufaro, S. Basaria, M. Ewertz, E. Rosenbaum et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 89(6), 2867–2872 (2004)PubMed
72.
go back to reference F. Basolo, E. Molinaro, L. Agate, A. Pinchera, L. Pollina, G. Chiappetta et al. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur. J. Endocrinol. 145(5), 599–604 (2001)PubMed F. Basolo, E. Molinaro, L. Agate, A. Pinchera, L. Pollina, G. Chiappetta et al. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur. J. Endocrinol. 145(5), 599–604 (2001)PubMed
Metadata
Title
A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma
Authors
Tahereh Haghzad
Babak Khorsand
S. Adeleh Razavi
Mehdi Hedayati
Publication date
17-06-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03911-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare